Short term survival of critically ill COVID-19 Egyptian patients on assisted ventilation treated by either Dexamethasone or Tocilizumab
Abstract Tocilizumab (TCZ) and Dexamethasone are used for the treatment of critically ill COVID-19 patients. We compared the short-term survival of critically ill COVID-19 patients treated with either TCZ or Dexamethasone. 109 critically ill COVID-19 patients randomly assigned to either TCZ therapy...
Guardado en:
Autores principales: | Alaa Rashad, Sherif Mousa, Hanaa Nafady-Hego, Asmaa Nafady, Hamed Elgendy |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/d624fcb811b942188fd42108c236ceba |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Therapeutic efficacy of macrolides in management of patients with mild COVID-19
por: Alaa Rashad, et al.
Publicado: (2021) -
SARS-CoV-2 PCR and antibody positivity among school staff at the beginning and end of the first school term
por: Moza Alishaq, et al.
Publicado: (2021) -
Effectiveness of Tocilizumab with and without Dexamethasone in Patients with Severe COVID-19: A Retrospective Study
por: Zarębska-Michaluk D, et al.
Publicado: (2021) -
Barotrauma, invasive ventilation, and timing of tocilizumab as predictors of mortality along with inflammatory markers and comorbidities in critically ill COVID-19 patients: A retrospective study
por: Kapil Zirpe, et al.
Publicado: (2021) -
Tocilizumab as a Therapeutic Agent for Critically Ill Patients Infected with SARS‐CoV‐2
por: Russell M. Petrak, et al.
Publicado: (2021)